Clinical Trials | May 19, 2026
Access to genomic testing, not therapy cost, is the biggest challenge
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
